ALS oral therapy slows disease progression in preclinical testing
M102, an experimental oral therapy designed to simultaneously activate two molecular pathways that protect against nerve cell damage, showed promise…
Articles by Marisa Wexler, MS
Experimental drug K9 for ALS joins Healey & AMG Center trial program
Inflammasome Therapeutics is teaming up with the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital…
BCI technology may give voice to Mandarin speakers with paralysis
Scientists have developed a brain-computer interface (BCI) capable of instantly translating a person’s thoughts into written Mandarin Chinese. The technology…
Imaging agent detects toxic protein clumps in ALS brain, data show
ACI-19626, an experimental compound designed to be used as a PET tracer, can selectively bind to abnormal clumps of the…
Experimental oral therapy SPG302 may slow ALS progression
SPG302, an experimental oral therapy for amyotrophic lateral sclerosis (ALS), was well tolerated in an early clinical trial, and…
Blood test may track ALS progression, speed diagnosis
A new blood test that analyzes tiny fragments of DNA released by dying cells may help diagnose amyotrophic lateral sclerosis…
ALS and MS have very strong geographic association, study finds
Amyotrophic lateral sclerosis (ALS) is more common in some parts of the U.S. than others, and it has a…
Diabetes adds greater risk of mobility loss in ALS: Study
People with amyotrophic lateral sclerosis (ALS) who also have diabetes tend to lose the ability to walk faster than…
ALS therapy EKZ-102 on track to enter clinical testing in 2026
EKZ-102, Eikonizo Therapeutics‘s experimental oral therapy for amyotrophic lateral sclerosis (ALS), is on track to enter early clinical…
Pridopidine Phase 3 trial to start enrolling early next year
A pivotal Phase 3 clinical trial testing the oral therapy pridopidine in people with amyotrophic lateral sclerosis (ALS)…